Tools
Tools
Ortuzar, Natalia, Karu, Kersti, Presa, Daniela, Morais, Goreti R., Sheldrake, Helen M., Shnyder, Steve D., Barnieh, Francis M., Loadman, Paul M., Patterson, Laurence H., Pors, Klaus and Searcey, Mark 
ORCID: https://orcid.org/0000-0003-2273-8949
(2021)
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
Bioorganic & Medicinal Chemistry, 40.
ISSN 0968-0896
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (661kB) | Preview |
Abstract
The duocarmycins belong to a class of agent which has great potential for use in cancer therapy. Their exquisite potency means they are too toxic for systemic use, and targeted approaches are required to unlock their clinical potential. In this study, we have explored seco-OH-chloromethylindoline (CI) duocarmycin-based bioprecursors for their potential for cytochrome P450 (CYP)-mediated cancer cell kill. We report on synthetic and biological explorations of racemic seco-CI-MI, where MI is a 5-methoxy indole motif, and dehydroxylated analogues. We show up to a 10-fold bioactivation of de-OH CI-MI and a fluoro bioprecursor analogue in CYP1A1-transfected cells. Using CYP bactosomes, we also demonstrate that CYP1A2 but not CYP1B1 or CYP3A4 has propensity for potentiating these compounds, indicating preference for CYP1A bioactivation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Science > School of Pharmacy |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 23 Apr 2021 23:49 |
| Last Modified: | 23 Oct 2022 02:23 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/79866 |
| DOI: | 10.1016/j.bmc.2021.116167 |
Actions (login required)
 |
View Item |